In the first half of the year, China's total outbound licensing deals for innovative drugs reached USD 110 billion, hitting a new record high.

Reporters from China Central Television (CCTV) learned today (the 13th) from the National Medical Products Administration that from January to June this year, the total value of outbound licensing deals for Chinese innovative drugs reached approximately USD 110 billion—equivalent to 80% of the full-year total for 2025—setting a new historical record. According to the latest statistics, as of June 30, there were 81 outbound licensing transactions involving Chinese innovative drugs, with a combined transaction value of approximately USD 110 billion, amounting to 80% of the projected total for all of 2025. The data further indicate that during the first half of this year, these outbound licensing deals spanned ten therapeutic areas, including oncology, metabolic diseases, immunology, and neurology, with the primary licensees based in the United States, the United Kingdom, France, and Italy.

AASTOCKSJul 13 17:20

Hong Kong Exchanges and Clearing Limited (HKEX, stock code: 00388.HK) has added 18 new weekly and monthly stock option classes.

Hong Kong Exchanges and Clearing Limited (HKEX, stock code: 00388.HK) announced that it will launch 18 new weekly and monthly equity options classes in phases on August 10, 17, and 31, 2026. The six equity options classes commencing trading on August 10 include: MINIMAX-W (00100.HK), ZTE Corporation (00763.HK), Zhipu AI (02513.HK), Kingsoft Cloud (03896.HK), Yangtze Optical Fibre and Cable Joint Stock Limited Company (06869.HK), and Ubtech Robotics (09880.HK). The six equity options classes commencing trading on August 17 include: Shandong Gold

AASTOCKSJul 13 13:43

Hong Kong Market Close (07.10) | Hang Seng Index Gains 0.6%; Commercial Spaceflight Stocks Rally in Afternoon Session; AI Computing Hardware Stocks Lead Declines

Hong Kong stocks staged a rally followed by a pullback today, with the three major indices seeing their gains narrow in the afternoon session and the Hang Seng Tech Index turning negative.

Zhitong FinanceJul 10 16:40

New edition of the National Essential Medicines List released, expanding coverage to benefit grassroots healthcare

Today (the 9th), the National Health Commission, the National Administration of Traditional Chinese Medicine, and the National Disease Control and Prevention Administration jointly released the 2026 edition of the National Essential Medicines List. The updated list expands from the previous 685 medicines to 794, comprising 476 chemical and biological products and 318 traditional Chinese patent medicines, better meeting the public’s basic medication needs for disease prevention and treatment. Preliminary estimates indicate that medicines included in the new list account for 71% of the total medicine usage volume in public healthcare institutions nationwide. According to the authorities, relevant departments will further promote the procurement and use management of essential medicines and enhance standardized prescribing practices, ensuring that healthcare institutions at all levels are adequately equipped.

AASTOCKSJul 9 13:23

Multinational pharmaceutical companies have acquired nearly $100 billion worth of pipelines from China in a single year—just as Chinese innovative drugs sat down at the table, they immediately played their strongest hand.

In 2026, the figures for Chinese innovative drugs going global appear almost unrealistically large: as of June, China’s license-out deals accounted for approximately 59.3% of the total global transaction value in this category (Source: PharmaGo NextPharma, June 2026). This is not merely about 'closing a few big deals,' but rather represents a structural shift in China’s role within the global pharmaceutical value chain. For ordinary investors, the key question is not 'which pharmaceutical stock will rise,' but rather what kind of revenue this business model actually generates, whether it is sustainable, and where the pitfalls lie. Below are five questions

businesstimes cnJul 8 13:58

Zhito Smart Connect HK Stock Connect Holdings Ratio Anomaly Statistics | July 8

Zhitong HK Connect Holding Ratio Anomaly Statistics | June 30, 2026

Zhitong FinanceJul 8 08:36